Expert opinion on management of moderate-to-severe atopic dermatitis in Qatar

References

• Steinhoff M, Ahmad F, Pandey A, et al. Neuroimmune communication regulating pruritus in atopic dermatitis. J Allergy Clin Immunol. 2022;149(6):1–11. doi: 10.1016/j.jaci.2022.03.010.
   PubMed Web of Science ®Google Scholar
• Abuabara K, Margolis DJ, Langan SM. The long-term course of atopic dermatitis. Dermatol Clin. 2017;35(3):291–297. doi: 10.1016/j.det.2017.02.003.
   PubMed Web of Science ®Google Scholar
• Fishbein AB, Silverberg JI, Wilson EJ, et al. Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract. 2020;8(1):91–101. doi: 10.1016/j.jaip.2019.06.044.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Christen-Zäch S, Taieb A, et al. ETFAD/EADV Eczema Task Force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–2744. doi: 10.1111/jdv.16892.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417–428. doi: 10.1016/j.anai.2020.12.020.
   PubMed Web of Science ®Google Scholar
• Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284–1293. doi: 10.1111/all.13401.
   PubMed Web of Science ®Google Scholar
• Patruno C, Napolitano M, Argenziano G, et al. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol. 2021;35(4):958–964. doi: 10.1111/jdv.17094.
   PubMed Web of Science ®Google Scholar
• Chello C, Carnicelli G, Sernicola A, et al. Atopic dermatitis in the elderly Caucasian population: diagnostic clinical criteria and review of the literature. Int J Dermatol. 2020;59(6):716–721. doi: 10.1111/ijd.14891.
   PubMed Web of Science ®Google Scholar
• Al-Afif KAM, Buraik MA, Buddenkotte J, et al. Understanding the burden of atopic dermatitis in Africa and the Middle east. Dermatol Ther. 2019;9(2):223–241. doi: 10.1007/s13555-019-0285-2.
   PubMed Web of Science ®Google Scholar
• Oommen BJ, Kadori WIM, Abdulmajeed J, et al. The prevalence of atopic dermatitis among children aged between 6 months and 12 years attending primary health care clinics in Qatar 2018–2019. Int J Res Med Sci. 2022;10(9):1872–1877. doi: 10.18203/2320-6012.ijrms20222261.
   Google Scholar
• Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2021;20:1–20.
   PubMedGoogle Scholar
• Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi: 10.1038/s41572-018-0001-z.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Eckert L, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74(3):491–498. doi: 10.1016/j.jaad.2015.10.043.
   PubMed Web of Science ®Google Scholar
• Steinhoff M, Schmelz M, Szabo IL, et al. Clinical presentation, management, and pathophysiology of neuropathic itch. Lancet Neurol. 2018;17(8):709–720. doi: 10.1016/S1474-4422(18)30217-5.
   PubMed Web of Science ®Google Scholar
• de Graaf M, Janmohamed SR, Schuttelaar MLA, et al. Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a Delphi consensus project mapping expert opinion in northern Europe. J Eur Acad Dermatol Venereol. 2022;36(11):2153–2165. doi: 10.1111/jdv.18410.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Ahluwalia J, Waldman A, et al. Current guidelines for the evaluation and management of atopic dermatitis: a comparison of the joint task force practice parameter and American Academy of Dermatology guidelines. J Allergy Clin Immunol. 2017;139: s 49–S57. doi: 10.1016/j.jaci.2017.01.009.
   Web of Science ®Google Scholar
• Lopez Carrera YI, Al Hammadi A, Huang YH, et al. Epidemiology, diagnosis, and treatment of atopic dermatitis in the developing countries of Asia, Africa, Latin America, and the Middle east: a review. Dermatol Ther. 2019;9(4):685–705. doi: 10.1007/s13555-019-00332-3.
   Web of Science ®Google Scholar
• Linstone HA, Turoff M. 2002. The Delphi method: techniques and applications [Internet]. Available from: http://is.njit.edu/pubs/delphibook/delphibook.pdf
   Google Scholar
• Alakeel A, Al Sheikh A, Alraddadi AA, et al. Management of atopic dermatitis in adults in Saudi Arabia: consensus recommendations from the dermatological expert group. Clin Cosmet Investig Dermatol. 2022;15:1435–1445. doi: 10.2147/CCID.S357178.
   PubMed Web of Science ®Google Scholar
• Avena-Woods C. Overview of atopic dermatitis. Am J Manag Care. 2017;23(8):S115–S123.
   PubMed Web of Science ®Google Scholar
• Celakovska J, Josef B, Ettler K, et al. Atopic dermatitis in adolescents and adults: the evaluation of association with other allergic diseases and parameters. Food Agri Immunol. 2017;28(6):933–948. doi: 10.1080/09540105.2017.1320358.
   Web of Science ®Google Scholar
• Bylund S, Kobyletzki LB, Svalstedt M, et al. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol. 2020;100(12):adv00160. doi: 10.2340/00015555-3510.
   PubMed Web of Science ®Google Scholar
• Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(1):8–16. doi: 10.1159/000370220.
   PubMed Web of Science ®Google Scholar
• Datsi A, Steinhoff M, Ahmad F, et al. Interleukin-31: the “itchy” cytokine in inflammation and therapy. Allergy. 2021;76(10):2982–2997. doi: 10.1111/all.14791.
   PubMed Web of Science ®Google Scholar
• Yu S, Li Y, Zhou Y, et al. Immune mediators and therapies for pruritus in atopic dermatitis and psoriasis. J Cutan Immunol Allergy. 2019;2(1):4–14. doi: 10.1002/cia2.12049.
   Google Scholar
• Pappa G, Sgouros D, Theodoropoulos K, et al. The IL-4/-13 axis and its blocking in the treatment of atopic dermatitis. J Clin Med. 2022;11(19):5633. doi: 10.3390/jcm11195633.
   PubMed Web of Science ®Google Scholar
• Sugaya M. The role of Th17-related cytokines in atopic dermatitis. Int J Mol Sci. 2020;21(4):1314. doi: 10.3390/ijms21041314.
   PubMed Web of Science ®Google Scholar
• Alkon N, Bauer WM, Krausgruber T, et al. Single-cell analysis reveals innate lymphoid cell lineage infidelity in atopic dermatitis. J Allergy Clin Immunol. 2022;149(2):624–639. doi: 10.1016/j.jaci.2021.07.025.
   PubMed Web of Science ®Google Scholar
• Cevikbas F, Wang X, Akiyama T, et al. A sensory neuron–expressed IL-31 receptor mediates T helper cell–dependent itch: involvement of TRPV1 and TRPA1. J Allergy Clin Immunol. 2014;133(2):448–460. doi: 10.1016/j.jaci.2013.10.048.
   PubMed Web of Science ®Google Scholar
• Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217–228. doi: 10.1016/j.cell.2017.08.006.
   PubMed Web of Science ®Google Scholar
• Steinhoff M, Oaklander AL, Szabó IL, et al. Neuropathic itch. Pain. 2019;160 Suppl 1(1):S11–S16. doi: 10.1097/j.pain.0000000000001551.
   PubMedGoogle Scholar
• Czarnowicki T, He H, Canter T, et al. Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood. J Allergy Clin Immunol. 2020;145(1):215–228. doi: 10.1016/j.jaci.2019.09.031.
   PubMed Web of Science ®Google Scholar
• Ali F, Vyas J, Andrew F. Counting the burden: atopic dermatitis and health-related quality of life. Acta Derm Venereol. 2020;100:adv00161. doi: 10.2340/00015555-3511.
   PubMed Web of Science ®Google Scholar
• Simpson E, Eckert L, Gadkari A, et al. Validation of the atopic dermatitis control tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol. 2019;19(1):15. doi: 10.1186/s12895-019-0095-3.
   PubMed Web of Science ®Google Scholar
• Clinical Review Report: Dupilumab (Dupixent): (Sanofi-Aventis Canada Inc.): Indication: Moderate-to-severe atopic dermatitis (AD) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018. Appendix 5, Validity of Outcomes Measures. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539234/
   Google Scholar
• Patel NU, D’Ambra V, Feldman SR. Increasing adherence with topical agents for atopic dermatitis. Am J Clin Dermatol. 2017;18(3):323–332. doi: 10.1007/s40257-017-0261-5.
   PubMed Web of Science ®Google Scholar
• Anderson P, Austin J, Lofland JH, et al. Inadequate disease control, treatment dissatisfaction, and quality-of-life impairments among us patients receiving topical therapy for atopic dermatitis. Dermatol Ther. 2021;11(5):1571–1585. doi: 10.1007/s13555-021-00580-2.
   Web of Science ®Google Scholar
• Pariser DM, Simpson EL, Gadkari A, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the atopic dermatitis control tool (ADCT©). Curr Med Res Opin. 2020;36(3):367–376. doi: 10.1080/03007995.2019.1699516.
   PubMed Web of Science ®Google Scholar
• Samuel C, Cornman H, Kambala A, et al. A review on the safety of using jak inhibitors in dermatology: clinical and laboratory monitoring. Dermatol Ther. 2023;13(3):729–749. doi: 10.1007/s13555-023-00892-5.
   Web of Science ®Google Scholar
• Product prescribing information of dupilumab [Internet]; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761055lbl.pdf
   Google Scholar
• Summary of product characteristics of dupilumab [Internet]. Available from: https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf
   Google Scholar
• Beck LA, Deleuran M, Bissonnette R, et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2022;23(3):393–408. doi: 10.1007/s40257-022-00685-0.
   PubMed Web of Science ®Google Scholar
• Product prescribing information of upadacitinib [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf
   Google Scholar
• Summary of product characteristics of upadacitinib [Internet]. Available from: https://www.ema.europa.eu/en/documents/product-information/rinvoq-epar-product-information_en.pdf
   Google Scholar
• Katoh N, Ohya Y, Murota H, et al. A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (rising up): an interim 24-week analysis. JAAD Int. 2022;6:27–36. doi: 10.1016/j.jdin.2021.11.001.
   PubMedGoogle Scholar
• Summary of product characteristics abrocitinib [Internet]. Available from: https://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_en.pdf
   Google Scholar
• Prescribing information of abrocitinib [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213871s000lbl.pdf
   Google Scholar
• Barcitinib FDA labelling information [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207924s000lbl.pdf
   Google Scholar
• Summary of product characteristics of barcitinib [Internet]. Available from: https://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_en.pdf
   Google Scholar
• Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242–255. doi: 10.1111/bjd.18898.
   PubMed Web of Science ®Google Scholar
• Tralokinumab prescribing information [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761180Orig1s000lbl.pdf
   Google Scholar
• Summary of product characteristics of tralokinumab [Internet]. Available from: https://www.ema.europa.eu/en/documents/product-information/adtralza-epar-product-information_en.pdf
   Google Scholar
• Prescribing information of cyclosporin [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050715s027,050716s028lbl.pdf
   Google Scholar
• Summary of product characteristics of cyclosporin [Internet]. Available from: https://www.ema.europa.eu/en/documents/referral/sandimmun-neoral-article-30-referral-annex-iii_en.pdf
   Google Scholar
• Methotrexate tablet [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008085s066lbl.pdf
   Google Scholar
• Summary of product characteristics of methotrexate [Internet]. Available from: https://www.ema.europa.eu/en/documents/product-information/jylamvo-epar-product-information_en.pdf
   Google Scholar
• Product monograph of azathioprine [Internet]. Available from: https://pdf.hres.ca/dpd_pm/00059993.PDF
   Google Scholar
• Summary of product characteristics of azathioprine [Internet]. Available from: https://www.ema.europa.eu/en/documents/product-information/jayempi-epar-product-information_en.pdf
   Google Scholar
• Mycophenolate mofetil capsules [Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050722s021,050723s019,050758s019,050759s024lbl.pdf
   Google Scholar
• Summary of product characteristics of mycophenolate mofetil [Internet]. Available from: https://www.ema.europa.eu/en/documents/product-information/mycophenolate-mofetil-teva-epar-product-information_en.pdf
   Google Scholar
• Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 24–27 Oct 22 [Internet]. Available from: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-24-27-october-2022
   Google Scholar